Global Drugmakers Partner with Chinese Biotechs

Global pharmaceutical companies increasingly turn to Chinese biotech firms for licensing deals involving experimental therapies. Recent agreements highlight growing cross-border collaborations targeting obesity, cancer, and other major diseases.

Xurve View
Insights:
The logo of Abogen Biosciences is pictured at their headquarters in Suzhou, China April 1, 2024. REUTERS/Andrew Silver

Rona Therapeutics signed an obesity drug licensing deal worth up to $1.16 billion with ROCHE HOLDING AG-BR, accelerating a wave of cross-border pharmaceutical partnerships. The agreement follows a surge of similar transactions between Western drugmakers and researchers in China. Global pharmaceutical giants are increasingly turning to Asian laboratories to secure experimental therapies and maintain competitive pipelines.